These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 19959491

  • 1. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 2. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 3. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [Abstract] [Full Text] [Related]

  • 4. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [Abstract] [Full Text] [Related]

  • 5. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 Jul; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 6. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
    Akinci B, Comlekci A, Ali Ozcan M, Demir T, Yener S, Demirkan F, Yuksel F, Yesil S.
    Endocr J; 2007 Feb; 54(1):45-52. PubMed ID: 17090955
    [Abstract] [Full Text] [Related]

  • 7. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N.
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [Abstract] [Full Text] [Related]

  • 8. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
    Dusse LM, Cooper AJ, Lwaleed BA.
    Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
    [Abstract] [Full Text] [Related]

  • 9. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006 Mar; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 10. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
    Ozeren M, Karahan SC, Ozgur M, Eminagaoglu S, Unsal M, Baytan S, Bozkaya H.
    Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
    [Abstract] [Full Text] [Related]

  • 11. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE.
    Thromb Res; 2006 Oct; 118(2):189-97. PubMed ID: 16055173
    [Abstract] [Full Text] [Related]

  • 12. [Study of fibrinolysis inhibitors in 117 acute leukemia patients].
    Wang W, Ji CY, Ye JJ, Zhu YY, Guo DM, Ji M.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):183-6. PubMed ID: 18788619
    [Abstract] [Full Text] [Related]

  • 13. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 14. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
    Kemona-Chetnik I, Kowal K, Kucharewicz I, Pampuch A, Bodzenta-Lukaszyk A.
    Przegl Lek; 2006 Aug; 63(12):1281-5. PubMed ID: 17642140
    [Abstract] [Full Text] [Related]

  • 15. Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia.
    Verkleij CJ, Stuijver DJ, van Zaane B, Squizzato A, Brandjes DP, Büller HR, Meijers JC, Gerdes VE.
    Thromb Haemost; 2013 Feb; 109(2):214-20. PubMed ID: 23197299
    [Abstract] [Full Text] [Related]

  • 16. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

  • 17. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation.
    Chen CC, Lee KD, Gau JP, Yu YB, You JY, Lee SC, Hsu HC, Chau WK, Ho CH.
    Ann Hematol; 2005 Oct; 84(10):675-80. PubMed ID: 16007424
    [Abstract] [Full Text] [Related]

  • 18. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
    Santamaría A, Borrell M, Oliver A, Ortín R, Forner R, Coll I, Mateo J, Souto JC, Fontcuberta J.
    Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
    [Abstract] [Full Text] [Related]

  • 19. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
    Boffa MB, Koschinsky ML.
    Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488
    [Abstract] [Full Text] [Related]

  • 20. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.
    Van Thiel DH, George M, Fareed J.
    Thromb Haemost; 2001 Apr; 85(4):667-70. PubMed ID: 11341503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.